Clariant Completes Strategic Expansion of Pharmaceutical Excipients and Specialty Chemicals Manufacturing in China
Thursday, November 06, 2025
Clariant, a global specialty chemicals leader, announced the completion of its state-of-the-art facility expansion at Daya Bay, China, on November 6, 2025. This strategic CHF 80-million investment marks a significant milestone in Clariant's Asia growth strategy, enhancing its manufacturing capacity, supply resilience, and product portfolio for pharmaceutical excipients and specialty chemicals. The development responds to rising demand from Asia's pharmaceutical, personal care, and home care sectors, strengthening Clariant's commitment to quality, innovation, and regional partnership.
The newly expanded Daya Bay site features a second spray tower dedicated to pharmaceutical excipient production, specifically designed to serve customers in southern China. This tower enables greater consistency in manufacturing Active Pharmaceutical Ingredients (APIs) used in laxatives and various excipients essential for drug formulation. As China’s pharma sector rapidly evolves, Clariant’s enhanced capabilities ensure the company plays an increasingly vital role in supporting drug makers with ingredients that meet stringent quality standards and regulatory compliance.
This expansion complements Clariant’s multi-purpose plant (MPP), which now houses an added reactor to support higher output of specialized chemicals. These include mild surfactants for personal care brands and soil release polymers for home care applications under Clariant’s Texcare range. Increased capacity aligns with rising demand for gentle, high-performance personal care goods and advanced home cleaning solutions in Asia. By centralizing these technologies in China, Clariant improves access for its regional clients, enabling more rapid development cycles and collaborative innovation tailored to local consumer needs.
In terms of sustainability and product performance, Daya Bay now produces a wider array of high-performance surfactants, such as water-based coatings that cut VOC emissions and synthetic lubricant ingredients that extend equipment lifespans. The expansion also boosts Clariant’s output of crop protection additives and soil health enhancers, opening new avenues in precision agriculture and resource-efficient farming in Asia. These additions highlight Clariant’s multi-sector approach and adaptability in supporting its partners’ sustainability and operational goals.
Ethylene Oxide Derivatives (EODs), a core component in pharmaceuticals, personal care, and industrial applications, have also seen a marked surge in production capacity at Daya Bay. By broadening the chemical portfolio and building integrated supply lines, Clariant is now positioned to better meet the requirements of Asian clients, from formulation R&D to large-scale manufacturing. The company’s expanded footprint allows for enhanced local collaboration, faster turnaround on custom solutions, and direct support for innovation pipelines aligned with Asian regulatory frameworks and market dynamics.
Christian Vang, Business President Care Chemicals at Clariant, emphasized the significance of the expansion: “This investment represents a pivotal moment for Clariant’s operations in China. By bringing our innovation and expertise closer to our customers’ businesses, we’re better positioned to support growth, drive developments forward, and help achieve sustainability targets as well as performance needs for both healthcare and personal care sectors.”
For pharma executives, researchers, and manufacturers in Asia, Clariant’s expanded Daya Bay facilities provide fewer supply chain bottlenecks, increased formulation capabilities, and reliable access to specialty ingredients vital for drug and consumer product innovation. With the dual focus on pharmaceutical excipients and specialty chemicals, the site now acts as a hub for both standardized production and rapid prototyping, sparking further collaboration with regional drug makers and solution providers.
As the Asian pharmaceutical industry continues to experience robust growth and innovation, Clariant's investment is expected to significantly shape ingredient availability, supply reliability, and next-generation formulation strategies throughout China and the wider region. The company’s commitment to quality, operational excellence, and customer-centered solution development positions it as a trusted partner for Asian businesses seeking cutting-edge specialty chemicals and pharma-grade excipients in a dynamically evolving market.
